Search research articles
Contact Us
Filters
Showing results (1-10 of 145) with videos related to
Page
of 15
Sort By:
Therapeutic Advances in Medical Oncology
|
December 17, 2021
Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
Valérie Gounant, Solenn Brosseau, Gérard Zalcman
La Revue Du Praticien
|
June 23, 2007
[Management of malignant pleural effusion]
Gérard Zalcman, Emmanuèle Lechapt, Emmanuel Bergot
Lung Cancer (Amsterdam, Netherlands)
|
September 7, 2011
Chemotherapy in elderly patients with advanced non-small cell lung cancer
Elisabeth Quoix, Virginie Westeel, Gérard Zalcman, et al.
Bulletin Du Cancer
|
June 30, 2015
[Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC]
Solenn Brosseau, Youssef Oulkhouir, Charles Naltet, et al.
Cell Death & Disease
|
December 6, 2019
RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis-an updated review
Fatéméh Dubois, Emmanuel Bergot, Gérard Zalcman, et al.
La Revue Du Praticien
|
December 5, 2018
[Malignant pleural mesothelioma: rare and aggressive but with new therapeutic perspectives]
Solenn Brosseau, Charles Naltet, Valérie Gounant, et al.
La Revue Du Praticien
|
December 5, 2018
[Therapeutic advances in lung cancer]
Solenn Brosseau, Charles Naltet, Valérie Gounant, et al.
Frontiers in Oncology
|
March 6, 2020
Antiangiogeneic Strategies in Mesothelioma
Anna K Nowak, Solenn Brosseau, Alistair Cook, et al.
Current Opinion in Oncology
|
November 16, 2010
Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer
Gérard Zalcman, Emmanuel Bergot, Christian Creveuil, et al.
Cellular and Molecular Life Sciences : CMLS
|
October 1, 2024
A review and perspective paper: Ras oncogene gets modest, from kingpin to mere henchman
Jacques H Camonis, Vasily N Aushev, Elina Zueva, et al.
Page
of 15
Search research articles
Search
Showing results (1-10 of 145) with videos related to
Sort By:
Page
of 15
Therapeutic Advances in Medical Oncology
|
December 17, 2021
Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
Valérie Gounant, Solenn Brosseau, Gérard Zalcman
La Revue Du Praticien
|
June 23, 2007
[Management of malignant pleural effusion]
Gérard Zalcman, Emmanuèle Lechapt, Emmanuel Bergot
Lung Cancer (Amsterdam, Netherlands)
|
September 7, 2011
Chemotherapy in elderly patients with advanced non-small cell lung cancer
Elisabeth Quoix, Virginie Westeel, Gérard Zalcman, et al.
Bulletin Du Cancer
|
June 30, 2015
[Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC]
Solenn Brosseau, Youssef Oulkhouir, Charles Naltet, et al.
Cell Death & Disease
|
December 6, 2019
RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis-an updated review
Fatéméh Dubois, Emmanuel Bergot, Gérard Zalcman, et al.
La Revue Du Praticien
|
December 5, 2018
[Malignant pleural mesothelioma: rare and aggressive but with new therapeutic perspectives]
Solenn Brosseau, Charles Naltet, Valérie Gounant, et al.
La Revue Du Praticien
|
December 5, 2018
[Therapeutic advances in lung cancer]
Solenn Brosseau, Charles Naltet, Valérie Gounant, et al.
Frontiers in Oncology
|
March 6, 2020
Antiangiogeneic Strategies in Mesothelioma
Anna K Nowak, Solenn Brosseau, Alistair Cook, et al.
Current Opinion in Oncology
|
November 16, 2010
Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer
Gérard Zalcman, Emmanuel Bergot, Christian Creveuil, et al.
Cellular and Molecular Life Sciences : CMLS
|
October 1, 2024
A review and perspective paper: Ras oncogene gets modest, from kingpin to mere henchman
Jacques H Camonis, Vasily N Aushev, Elina Zueva, et al.
Page
of 15